You are here
P&T March 2018
Some Action, Some Results, Some Questions
The Food and Drug Administration has made significant progress implementing some of the 60 provisions of the 21st Century Cures Act passed in 2016. The author discusses the successes and shortcomings of the agency’s regulatory activities.
The author reviews the latest improvements and advancements in the pharmaceutical supply chain, including those in packaging, monitoring, warehousing, and regulation.
Through a regional survey, researchers found that updated uniform practice guidelines are needed for alcohol withdrawal syndrome, particularly for severe cases.
The authors describe how a multihospital health system P&T committee standardized a formulary in an expedited manner before implementation of a system-wide EMR.
This retrospective study shows that a compounded oral vitamin K solution confers a significant price advantage for similar effect compared with the tablet formulation.
We present sessions on hepatocellular carcinoma and colorectal and pancreatic cancers from ASCO GI.
Key sessions from SABCS covered dose intensification, new trial data, and ovarian suppression to preserve fertility.
Container mix-ups and syringe swaps in the surgical environment
NIH starts to spend billions in Cures drug research money
Approvals, new indications, regulatory activities, and more
Zoster vaccine recombinant, adjuvanted (Shingrix) for the prevention of shingles in adults; angiotensin II injection (Giapreza) to increase blood pressure in adults with septic or other distributive shock; and glycopyrrolate inhalation solution (Lonhala Magnair) for the maintenance treatment of chronic obstructive pulmonary disease
Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections
Letter to the Editor